Your Messages Inbox
Your Article Summary
See Latest ArticlesAbbott and GSK to Collaborate on Molecular Diagnostic Test to Select Candidate Patients for Future Cancer Immunotherapy
Abbott, 07/14/09
Abbott announced today that it has entered into an agreement with GlaxoSmithKline to develop an automated molecular diagnostic test, based on polymerase chain reaction technology, intended to screen non-small cell lung cancer tumors for expression of the MAGE-A3 antigen. GSK's MAGE-A3 ASCI candidate is currently being evaluated as an adjuvant treatment in resected NSCLC in the Phase III clinical study MAGRIT, the largest lung cancer treatment study ever conducted. To be eligible to receive GSK's MAGE A3 ASCI, patients must have MAGE-A3 expressing NSCLC tumors.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi-aventis to acquire Oenobiol, French leader in nutritional beauty supplements
Sanofi-aventis, 11/02/09
Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
Chugai Pharmaceutical Co., 11/04/09
Article Search
Sponsor